Research Foundation for Mental Hygiene
New York, 10032, United States
NCT Number: NCT00000271
The purpose of this study is to measure the effect of desipramine in cocaine abusers selected for major depression or dysthymia.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
New York, 10032, United States
This is a randomized, 12-week, double-blind, 'placebo-controlled trial of outpatients meeting DSM-III-R criteria for cocaine dependence and major depression or dysthymia (by SCID interview). Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All patients received weekly individual manual-guided relapse prevention therapy. Weekly outcome measures included the Clinical Global Impression Scale, self-reported cocaine use and craving, urine toxicology, and the Hamilton Depression Scale.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion:
Exclusion:
Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
Other names: desmethylimipramine
Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
Time frame: Weekly over a 12 week period.
Clinical Global Impression Scale, self-reported cocaine use and craving, urine toxicology.
Time frame: Bi-weekly over a 12 week period.
Hamilton Depression Scale
New York State Psychiatric Institute
Other
New Approaches to Cocaine Abuse Medications (A)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00232336
Behavior, Behavior, Addictive
Tacoma, Washington, United States
View Trial DetailsNCT00000216
Chemically-Induced Disorders, Cocaine-Related Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT00000311
Chemically-Induced Disorders, Cocaine-Related Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT00000317
Chemically-Induced Disorders, Cocaine-Related Disorders
New York, United States
View Trial Details